FDA Approves Bayer Kerendia for Type 1 Diabetes CKD
Analysis based on 11 articles · First reported Sep 17, 2026 · Last updated Sep 17, 2026
The approval expands Bayer's Kerendia franchise into a new indication with no approved competition in over three decades, potentially adding meaningful revenue growth for the company's pharmaceuticals division and supporting its stock. Broader market impact is limited, as the news is company-specific and unlikely to move major indexes, though it reinforces positive sentiment for the pharmaceutical sector and kidney disease treatment developers.
Bayer announced on September 17, 2026 that the U.S. United States — Food and Drug Administration approved Kerendia (finerenone) for the treatment of adult patients with chronic kidney disease associated with type 1 diabetes. The approval marks the first new FDA-approved treatment option in more than 30 years for this patient population and represents the third approved U.S. indication for Kerendia, following its 2021 approval for chronic kidney disease associated with type 2 diabetes and its 2025 approval for symptomatic chronic heart failure with left ventricular ejection fraction of at least 40 percent. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist sold in 10 mg and 20 mg doses, is now indicated to reduce the urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate decline and end-stage kidney disease. The decision follows the FDA's Priority Review of Bayer's supplemental New Drug Application, granted in May 2026, and is supported by results from the Phase III FINE-ONE trial in adults with CKD and type 1 diabetes, along with additional Phase III data from the FIDELIO-DKD and FIGARO-DKD trials in CKD associated with type 2 diabetes. In FINE-ONE, finerenone plus standard of care significantly reduced the primary endpoint of relative change in UACR by 25 percent over six months compared with placebo. The FINE-ONE results were published in the The New England Journal of Medicine in March 2026 and presented in November 2025 at the American Society of Nephrology's Kidney Week. Approximately 20-30 percent of people with type 1 diabetes in the U.S. also have CKD. With this decision, the U.S. is the only country where Kerendia is approved for the treatment of adults with chronic kidney disease associated with type 1 diabetes. Bayer shares were trading at 48.98 euros at previous close on the Frankfurt Exchange.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard